<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="hsr270432" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Health Sci Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2398-8835</journal-id><journal-id journal-id-type="publisher-id">HSR2</journal-id><journal-title-group><journal-title>Health Science Reports</journal-title></journal-title-group><issn pub-type="epub">2398-8835</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39917596</article-id><article-id pub-id-type="pmc">PMC11798733</article-id>
<article-id pub-id-type="doi">10.1002/hsr2.70432</article-id><article-id pub-id-type="publisher-id">HSR270432</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>First&#x02010;Line Levofloxacin&#x02010;Based Triple Therapy Versus Standard Bismuth&#x02010;Based Quadruple Therapy for <italic toggle="yes">Helicobacter pylori</italic> Eradication in Saudi Arabia: A Retrospective Single&#x02010;Center Study</article-title></title-group><contrib-group><contrib id="hsr270432-cr-0001" contrib-type="author"><name><surname>Abdulqader</surname><given-names>Abdulrhman Khaled Al</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0008-0435-8081</contrib-id><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hsr270432-cr-0002" contrib-type="author"><name><surname>Alamri</surname><given-names>Turki Abdullah</given-names></name><xref rid="hsr270432-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hsr270432-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hsr270432-cr-0003" contrib-type="author"><name><surname>Alhamad</surname><given-names>Mahdi Abdullah</given-names></name><xref rid="hsr270432-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="hsr270432-cr-0004" contrib-type="author" corresp="yes"><name><surname>Shehab El&#x02010;Deen</surname><given-names>Somaia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1429-0363</contrib-id><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hsr270432-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>sdarwish@kfu.edu.sa</email><email>Somaia.shehab@med.menofia.edu.eg</email></address></contrib><contrib id="hsr270432-cr-0005" contrib-type="author"><name><surname>Essa</surname><given-names>Abdallah</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6542-8532</contrib-id><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hsr270432-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="hsr270432-cr-0006" contrib-type="author"><name><surname>Alfayez</surname><given-names>Raed Abdullah</given-names></name><xref rid="hsr270432-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="hsr270432-cr-0007" contrib-type="author"><name><surname>Albaqshi</surname><given-names>Baqer Mohammed</given-names></name><xref rid="hsr270432-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="hsr270432-cr-0008" contrib-type="author"><name><surname>Almajed</surname><given-names>Adnan Salah</given-names></name><xref rid="hsr270432-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="hsr270432-cr-0009" contrib-type="author"><name><surname>Alhassan</surname><given-names>Mohammed Yousef</given-names></name><xref rid="hsr270432-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="hsr270432-cr-0010" contrib-type="author"><name><surname>Essa</surname><given-names>Ali</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-8211-0632</contrib-id><xref rid="hsr270432-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="hsr270432-cr-0011" contrib-type="author"><name><surname>Albadrani</surname><given-names>Ahmed Abdullah</given-names></name><xref rid="hsr270432-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="hsr270432-cr-0012" contrib-type="author"><name><surname>Alomair</surname><given-names>Omar</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8498-1621</contrib-id><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hsr270432-cr-0013" contrib-type="author"><name><surname>Al Jalal</surname><given-names>Bashaeer Abdullh</given-names></name><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hsr270432-cr-0014" contrib-type="author"><name><surname>Almulhim</surname><given-names>Mohammed Yousef</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-6347-4743</contrib-id><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hsr270432-cr-0015" contrib-type="author"><name><surname>Alotaibi</surname><given-names>Abdullah</given-names></name><xref rid="hsr270432-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hsr270432-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hsr270432-cr-0016" contrib-type="author"><name><surname>Darwish</surname><given-names>Ehab</given-names></name><xref rid="hsr270432-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hsr270432-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="hsr270432-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Department</named-content>
<institution>College of Medicine, King Faisal University</institution>
<city>Al&#x02010;Ahsa</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Department, Gastroenterology Unit</named-content>
<institution>King Fahad University Hospital</institution>
<city>Al Khobar</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Imam Abdulrahman Bin Faisal University</institution>
<city>Dammam</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>King Fahad Specialist Hospital</institution>
<city>Dammam</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Tropical Medicine Department, Faculty of Medicine</named-content>
<institution>Menoufia University</institution>
<city>Shebin El&#x02010;Kom</city>
<country country="EG">Egypt</country>
</aff><aff id="hsr270432-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>King Fahad Medical City</institution>
<city>Riyadh</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>King Saud Medical City</institution>
<city>Riyadh</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>College of Medicine, King Faisal University</institution>
<city>Al-Ahsa</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Faculty of Medicine, Menoufia University</institution>
<city>Shebin El&#x02010;Kom</city>
<country country="EG">Egypt</country>
</aff><aff id="hsr270432-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Internal Medicine Department</named-content>
<institution>College of Medicine, Prince Sattam Bin Abdulaziz University</institution>
<city>Al&#x02010;Kharj</city>
<country country="SA">Kingdom of Saudi Arabia</country>
</aff><aff id="hsr270432-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine</named-content>
<institution>Zagazig University</institution>
<city>Zagazig</city>
<country country="EG">Egypt</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Somaia Shehab El&#x02010;Deen (<email>sdarwish@kfu.edu.sa</email>; <email>Somaia.shehab@med.menofia.edu.eg</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>8</volume><issue seq="93">2</issue><issue-id pub-id-type="doi">10.1002/hsr2.v8.2</issue-id><elocation-id>e70432</elocation-id><history>
<date date-type="rev-recd"><day>12</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>17</day><month>9</month><year>2024</year></date>
<date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Health Science Reports published by Wiley Periodicals LLC.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Health Science Reports</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:HSR2-8-e70432.pdf"/><abstract><title>ABSTRACT</title><sec id="hsr270432-sec-0010"><title>Background and Aims</title><p>Antibiotic resistance in Saudi Arabia has led to decreased efficacy of conventional triple therapy for <italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) eradication, prompting the development of alternative treatments like levofloxacin&#x02010;based triple and bismuth&#x02010;based quadruple therapies. However, comparative data regarding its efficacy are lacking. Therefore, this study's goal was to compare the efficacy of levofloxacin&#x02010;based triple therapy with that of standard bismuth&#x02010;based quadruple therapy as first&#x02010;line regimens.</p></sec><sec id="hsr270432-sec-0020"><title>Methods</title><p>This retrospective analysis included 197 treatment&#x02010;na&#x000ef;ve adults with <italic toggle="yes">H. pylori</italic> infection who received levofloxacin&#x02010;based triple (levofloxacin&#x02009;+&#x02009;amoxicillin&#x02009;+&#x02009;PPI) therapy (<italic toggle="yes">n</italic>&#x02009;=&#x02009;81) or standard bismuth&#x02010;based quadruple (bismuth&#x02009;+&#x02009;tetracycline&#x02009;+&#x02009;metronidazole&#x02009;+&#x02009;PPI) therapy (<italic toggle="yes">n</italic>&#x02009;=&#x02009;116). <italic toggle="yes">H. pylori</italic> eradication was evaluated 4&#x02013;8 weeks after medication administration using the <sup>13</sup>C&#x02010;urea breath test, and variables that could affect the rate of success were examined.</p></sec><sec id="hsr270432-sec-0030"><title>Results</title><p>There were no differences between groups in terms of age, sex, nationality, or type of proton pump inhibitor (PPI) used. The bismuth&#x02010;based quadruple therapy group exhibited a markedly superior success rate compared to the levofloxacin&#x02010;based triple therapy group when the latter was administered for 7 or 10 days (81.03% vs. 6.66%, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, and 81.03% vs. 36.1%, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). However, when the levofloxacin&#x02010;based triple therapy was extended to 14 days, its <italic toggle="yes">H. pylori</italic> eradication rate became comparable to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy (81.03% vs. 80%, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.898). Eradication rates for both regimens were similar for patients aged &#x02265;&#x02009;60, non&#x02010;Saudi, when using omeprazole and those treated with levofloxacin&#x02010;based triple therapy for 14 days.</p></sec><sec id="hsr270432-sec-0040"><title>Conclusion</title><p>Quadruple treatment based on bismuth is superior to triple therapy based on levofloxacin for eradicating <italic toggle="yes">H. pylori</italic> in Saudi Arabia and should be used as a first&#x02010;line treatment. However, the 14&#x02010;day levofloxacin&#x02010;based triple treatment had an <italic toggle="yes">H. pylori</italic> eradication rate comparable to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy.</p></sec></abstract><kwd-group><kwd id="hsr270432-kwd-0001">bismuth</kwd><kwd id="hsr270432-kwd-0002">efficacy</kwd><kwd id="hsr270432-kwd-0003">eradication</kwd><kwd id="hsr270432-kwd-0004"><italic toggle="yes">H. pylori</italic></kwd><kwd id="hsr270432-kwd-0005">levofloxacin</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>The authors received no specific funding for this work.</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="8"/><word-count count="5590"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="hsr270432-sec-0050"><label>1</label><title>Introduction</title><p>
<italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) infection is a highly prevalent global infection. Although developed countries have witnessed a decline in <italic toggle="yes">H. pylori</italic> prevalence owing to better sanitation and increased antibiotic usage, <italic toggle="yes">H. pylori</italic> remains highly prevalent (&#x0003e;&#x02009;50%) in most other countries [<xref rid="hsr270432-bib-0001" ref-type="bibr">1</xref>]. Infection is primarily responsible for peptic ulcer disease, mucosa&#x02010;associated lymphoid tissue lymphoma (MALT lymphoma), and gastric adenocarcinoma, and eradication is crucial for preventing or treating these diseases [<xref rid="hsr270432-bib-0002" ref-type="bibr">2</xref>]. Traditionally, standard triple treatment, comprising a proton pump inhibitor (PPI) in conjunction with two antibiotics, has achieved an eradication rate exceeding 80% for <italic toggle="yes">H. pylori</italic> [<xref rid="hsr270432-bib-0003" ref-type="bibr">3</xref>]. However, the efficacy of conventional treatments has been decreasing owing to rising global resistance to both clarithromycin and metronidazole [<xref rid="hsr270432-bib-0004" ref-type="bibr">4</xref>]. In Saudi Arabia, the prevalence of clarithromycin&#x02010;resistant <italic toggle="yes">H. pylori</italic> ranges from 8.8% to 39.9%, whereas resistance to metronidazole ranges from 48.5% to 80%, indicating significant resistance rates [<xref rid="hsr270432-bib-0005" ref-type="bibr">5</xref>, <xref rid="hsr270432-bib-0006" ref-type="bibr">6</xref>]. Therefore, unless antimicrobial susceptibility testing is performed, conventional triple therapy for 10&#x02013;14 days is not advised for <italic toggle="yes">H. pylori</italic> treatment. Instead, bismuth&#x02010;based quadruple therapy for 10&#x02013;14 days is now considered the preferred first&#x02010; and second&#x02010;line treatment, as recommended by the Saudi <italic toggle="yes">H. pylori</italic> Working Group [<xref rid="hsr270432-bib-0006" ref-type="bibr">6</xref>]. Numerous studies have demonstrated the effectiveness of levofloxacin&#x02010;containing triple therapy as second&#x02010; and third&#x02010;line therapy [<xref rid="hsr270432-bib-0007" ref-type="bibr">7</xref>, <xref rid="hsr270432-bib-0008" ref-type="bibr">8</xref>, <xref rid="hsr270432-bib-0009" ref-type="bibr">9</xref>, <xref rid="hsr270432-bib-0010" ref-type="bibr">10</xref>]. Levofloxacin&#x02010;containing triple therapy is also a successful first&#x02010;line therapy according to some studies [<xref rid="hsr270432-bib-0011" ref-type="bibr">11</xref>, <xref rid="hsr270432-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270432-bib-0013" ref-type="bibr">13</xref>]. Data on the effectiveness and duration of bismuth&#x02010;containing quadruple treatment with levofloxacin&#x02010;containing triple therapies are debatable. Some studies have shown that 1&#x02010;week quadruple treatments comprising bismuth and levofloxacin are effective first&#x02010;line treatments. Nevertheless, further research has shown that these regimens are unsuccessful when used as second&#x02010;line treatment [<xref rid="hsr270432-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270432-bib-0015" ref-type="bibr">15</xref>].</p><p>Considering the significance of local antibiotic&#x02010;resistance patterns, it is imperative to select treatment plans tailored to specific contexts. Consequently, our study aimed to investigate and compare the efficacy of levofloxacin&#x02010;based triple therapy with that of standard bismuth&#x02010;based quadruple therapy as the first&#x02010;line regimen for <italic toggle="yes">H. pylori</italic> eradication in Saudi Arabia.</p></sec><sec sec-type="methods" id="hsr270432-sec-0060"><label>2</label><title>Methods</title><sec id="hsr270432-sec-0070"><label>2.1</label><title>Study Design and Patients</title><p>This retrospective study was conducted at the Dr. Sulaiman Al&#x02010;Habib Hospital in the eastern region of Saudi Arabia from January 2020 to August 2023. The study included adult patients diagnosed with <italic toggle="yes">H. pylori</italic> infection in gastroenterology clinics, identified by either histology or <sup>13</sup>C&#x02010;urea breath test (UBT), who received treatment with either levofloxacin&#x02010;based triple therapy (Group I) or bismuth&#x02010;based quadruple therapy (Group II).</p><p>Patients with incomplete medical records, patients who received alternative treatment regimens, those who had previously attempted to eradicate <italic toggle="yes">H. pylori</italic>, those who had received treatment in the 4&#x02013;6 weeks before UBT with an H<sub>2</sub> receptor antagonist, PPI, or antibiotics, those who had stopped treatment early for any reason, and those who did not adhere to treatment were excluded. A <sup>13</sup>C&#x02010;urea breath test was used to assess the rate of <italic toggle="yes">H. pylori</italic> eradication 4&#x02013;8 weeks after therapy, and factors that might affect this rate of success were examined.</p></sec><sec id="hsr270432-sec-0080"><label>2.2</label><title>Therapeutic Regimens</title><p>Patients in Group I received levofloxacin&#x02010;based triple therapy: levofloxacin 500&#x02009;mg once a day, amoxicillin 1&#x02009;g twice a day, and PPI twice a day for 7, 10, or 14 days. Group II received Pylera (140&#x02009;mg bismuth subcitrate potassium, 125&#x02009;mg metronidazole, and 125&#x02009;mg tetracycline hydrochloride) three capsules four times daily after meals and before sleep, plus PPI (omeprazole 20&#x02009;mg, lansoprazole 30&#x02009;mg, esomeprazole 40&#x02009;mg, or pantoprazole 40&#x02009;mg) twice daily before meals for 10 days. The PPI selection in both groups was determined by the prescribing physician.</p></sec><sec id="hsr270432-sec-0090"><label>2.3</label><title>Ethical Consideration</title><p>The Institutional Review Board of King Faisal University approved this research (KFU&#x02010;REC&#x02010;2024&#x02010;MAR&#x02010;ETHICS2147) and waived the requirement for patient consent owing to its retrospective nature. The study adhered to the Helsinki Declaration, anonymized the data, and conducted aggregate analysis.</p></sec><sec id="hsr270432-sec-0100"><label>2.4</label><title>Statistical Analysis</title><p>Statistical analyses were performed using SPSS (v 26.0; IBM Corporation, Armonk, NY, USA). Continuous variables were presented as mean&#x02009;&#x000b1;&#x02009;standard deviation, whereas categorical variables were presented as numbers and percentages. The Chi&#x02010;squared test or Fisher's exact test was used to compare categorical variables, and the <italic toggle="yes">t</italic>&#x02010;test was used to compare continuous variables. Statistical significance was set at <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="results" id="hsr270432-sec-0110"><label>3</label><title>Results</title><sec id="hsr270432-sec-0120"><label>3.1</label><title>Study Group Demographics</title><p>A total of 197 treatment&#x02010;na&#x000ef;ve adults with <italic toggle="yes">H. pylori</italic> infection were included in our study. Eighty&#x02010;one patients received levofloxacin&#x02010;based triple therapy and 116 patients received bismuth&#x02010;based quadruple therapy. The relevant demographic characteristics of the study population are provided in Table&#x000a0;<xref rid="hsr270432-tbl-0001" ref-type="table">1</xref>. There were no significant differences between the two groups regarding age, sex, nationality, or type of PPI used.</p><table-wrap position="float" id="hsr270432-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>The basic characteristics of the two groups of patients.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Group I (Levofloxacin&#x02010;based triple therapy)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Group II (Bismuth&#x02010;based quadruple Therapy)</th><th rowspan="2" align="center" valign="bottom" colspan="1">Test</th><th rowspan="2" align="center" valign="bottom" colspan="1">
<italic toggle="yes">p</italic> value</th></tr><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;81</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x02009;=&#x02009;116</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">40.99&#x02009;&#x000b1;&#x02009;13.1</td><td align="center" valign="top" rowspan="1" colspan="1">41.2&#x02009;&#x000b1;&#x02009;13.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.128<sup>T</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">40 (49.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (55.2%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">41 (50.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (44.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64<sup>C</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nationality</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Saudi</td><td align="center" valign="top" rowspan="1" colspan="1">77 (95.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">106 (91.4%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;Saudi</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (8.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.98<sup>C</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PPI</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="top" rowspan="1" colspan="1">10 (12.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (12.9%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="top" rowspan="1" colspan="1">11 (13.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (19%)</td><td align="center" valign="top" rowspan="1" colspan="1">5.056<sup>C</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pantoprazole</td><td align="center" valign="top" rowspan="1" colspan="1">24 (29.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (38.8%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Esomeprazole</td><td align="center" valign="top" rowspan="1" colspan="1">36 (44.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (29.3%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment duration</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">7 days</td><td align="center" valign="top" rowspan="1" colspan="1">15 (18.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">10 days</td><td align="center" valign="top" rowspan="1" colspan="1">36 (44.44%)</td><td align="center" valign="top" rowspan="1" colspan="1">116 (100%)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">14 days</td><td align="center" valign="top" rowspan="1" colspan="1">30 (37%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="hsr270432-tbl1-note-0001"><p>Abbreviations: PPI; proton pump inhibitor, T; <italic toggle="yes">t</italic>&#x02010;test, C; Chi&#x02010;square test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="hsr270432-sec-0130"><label>3.2</label><title>Efficacy in <italic toggle="yes">H. pylori</italic> Eradication</title><p>The effectiveness of both eradication regimens is shown in Figure&#x000a0;<xref rid="hsr270432-fig-0001" ref-type="fig">1</xref>. The overall eradication rate was 67% (132/197). The eradication rate in Group I was 6.66% (1/15) for those who received levofloxacin&#x02010;based triple therapy for 7 days, and 36.1% (13/36) for those who received it for 10 days, and 80% (24/30) for those who received it for 14 days. While the eradication rate was 81.03% (94/116) in Group II, which received bismuth&#x02010;based quadruple therapy (for 10 days). Therefore, when the levofloxacin&#x02010;based triple therapy is used for 7 or 10 days, the bismuth&#x02010;based quadruple therapy group had a significantly higher success rate than the levofloxacin&#x02010;based triple therapy group, but when it is used for 14 days, the <italic toggle="yes">H. pylori</italic> eradication rate is equivalent to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy.</p><fig position="float" fig-type="Figure" id="hsr270432-fig-0001"><label>Figure 1</label><caption><p>Efficacy in <italic toggle="yes">Helicobacter pylori</italic> eradication with both treatment regimens.</p></caption><graphic xlink:href="HSR2-8-e70432-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="hsr270432-sec-0140"><label>3.3</label><title>Comparing the Studied Groups Categorized According to Their Outcomes</title><p>As shown in Table&#x000a0;<xref rid="hsr270432-tbl-0002" ref-type="table">2</xref>, there were no statistical differences in eradication rates between the two regimens in patients aged &#x02265;&#x02009;60 years, in non&#x02010;Saudi patients, when omeprazole was used, and in patients treated with levofloxacin&#x02010;based triple therapy for 14 days.</p><table-wrap position="float" id="hsr270432-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Comparison between the studied groups categorized according to their outcomes.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">
<p>Group I (Levofloxacin&#x02010;based triple therapy)</p>
<p>(<italic toggle="yes">N</italic>&#x02009;=&#x02009;81)</p>
</th><th colspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">
<p>Group II (Bismuth&#x02010;based quadruple therapy)</p>
<p>(<italic toggle="yes">N</italic>&#x02009;=&#x02009;116)</p>
</th><th align="center" rowspan="3" valign="bottom" colspan="1">Chi&#x02010;square/Fisher's exact test</th><th align="center" rowspan="3" valign="bottom" colspan="1">
<italic toggle="yes">p</italic> value</th></tr><tr valign="bottom"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Success</th><th align="center" valign="bottom" rowspan="1" colspan="1">Failure</th><th align="center" valign="bottom" rowspan="1" colspan="1">Success</th><th align="center" valign="bottom" rowspan="1" colspan="1">Failure</th></tr><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x02009;=&#x02009;38</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x02009;=&#x02009;43</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x02009;=&#x02009;94</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#x02009;=&#x02009;22</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02009;&#x0003c;&#x02009;60 years</p>
<p>&#x02009;&#x02265;&#x02009;60 years</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>35/74 (47.3%)</p>
<p>3/7 (42.9%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>39/74 (52.7%)</p>
<p>4/7 (57.1%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>86/105 (81.9%)</p>
<p>8/11 (72.7%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19/105 (18%)</p>
<p>3/11 (27.3%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>23.7</p>
<p>1.6</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.2</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02009;Male</p>
<p>&#x02009;Female</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19/40 (47.5%)</p>
<p>19/41 (46.3%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>21/40 (52.5%)</p>
<p>22/41 (53.7%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>52/64 (81.3%)</p>
<p>42/52 (80.8%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>12/64 (18.8%)</p>
<p>10/52 (19.2%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>12.9</p>
<p>12.03</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nationality</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02009;Saudi</p>
<p>&#x02009;Non&#x02010;Saudi</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>36/77 (46.8%)</p>
<p>2/4 (50%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>41/77 (53.2%)</p>
<p>2/4 (50%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>84/106 (79.2%)</p>
<p>10/10 (100%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>22/106 (20.8%)</p>
<p>0/10 (0%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>20.9</p>
<p>&#x02014;</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>&#x02014;</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type of PPI</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02009;Omeprazole</p>
<p>&#x02009;Lansoprazole</p>
<p>&#x02009;Pantoprazole</p>
<p>&#x02009;Esomeprazole</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>5/10 (50%)</p>
<p>5/11 (45.5%)</p>
<p>10/24 (41.7%)</p>
<p>18/36 (50%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>5/10 (50%)</p>
<p>6/11 (54.5%)</p>
<p>14/24 (58.3%)</p>
<p>18/36 (50%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>13/15 (86.7%)</p>
<p>18/22 (81.8%)</p>
<p>33/45 (73.3%)</p>
<p>30/34 (88.2%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>2/15 (13.3%)</p>
<p>4/22 (18.1%)</p>
<p>12/45 (26.7%)</p>
<p>4/34 (11.8%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>2.48</p>
<p>4.59</p>
<p>6.68</p>
<p>11.86</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.075</p>
<p>
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.03<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Treatment duration</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>
<list list-type="simple"><list-item><label>&#x025aa;</label><p>7 days for GI vs. 10 days for GII</p></list-item><list-item><label>&#x025aa;</label><p>10 days for GI vs. 10 days for GII</p></list-item><list-item><label>&#x025aa;</label><p>14 days for GI vs. 10 days for GII</p></list-item></list>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>1/15 (6.66%)</p>
<p>13/36 (36.1%)</p>
<p>24/30 (80%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>14/15 (93.3%)</p>
<p>23/36 (63.9%)</p>
<p>6/30 (20%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>94/116 (81%)</p>
<p>94/116 (81%)</p>
<p>94/116 (81%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>22/116 (19%)</p>
<p>22/116 (19%)</p>
<p>22/116 (19%)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>10.58</p>
<p>26.6</p>
<p>0.017</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001<xref rid="hsr270432-tbl2-note-0001" ref-type="table-fn">*</xref>
</p>
<p>
<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.89</p>
</td></tr></tbody></table><table-wrap-foot><fn id="hsr270432-tbl2-note-0001"><label>*</label><p>Significant at <italic toggle="yes">p</italic>&#x02009;&#x02264;&#x02009;0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec sec-type="discussion" id="hsr270432-sec-0150"><label>4</label><title>Discussion</title><p>
<italic toggle="yes">H. pylori</italic> is a prevalent bacterial infection that can cause chronic gastritis, duodenal and stomach ulcers, gastric adenocarcinoma, and gastric MALT lymphoma [<xref rid="hsr270432-bib-0016" ref-type="bibr">16</xref>]. It remains unknown how best to treat treatment&#x02010;na&#x000ef;ve patients with <italic toggle="yes">H. pylori</italic> infection. Therefore, this study aimed to evaluate the effectiveness of triple therapy with levofloxacin and quadruple therapy with bismuth as the first&#x02010;line regimen in Saudi Arabia.</p><p>In the current study, the eradication rate in Group I (levofloxacin&#x02010;based triple therapy) was 6.66% for those who received levofloxacin&#x02010;based triple therapy for 7 days, 36.1% for those who received it for 10 days, and 80% for those who received it for 14 days, whereas that in Group II (bismuth&#x02010;based quadruple therapy) was 81.03%. So, the bismuth&#x02010;based quadruple treatment group had a significantly higher success rate than the levofloxacin&#x02010;based triple therapy group when the latter was given for 7 or 10 days. Nonetheless, when the levofloxacin&#x02010;based triple treatment was prolonged to 14 days, its <italic toggle="yes">H. pylori</italic> eradication rate became equivalent to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy.</p><p>According to a Turkish study, the eradication rate of bismuth quadruple therapy was greater than that of levofloxacin&#x02010;containing triple therapy (88.3% vs. 74.8%) [<xref rid="hsr270432-bib-0017" ref-type="bibr">17</xref>]. In a different multicenter study conducted in Vietnam, the <italic toggle="yes">H. pylori</italic> eradication rates were 84.1% with a bismuth&#x02010;containing quadruple regimen and 77.4% with levofloxacin triple therapy (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) [<xref rid="hsr270432-bib-0018" ref-type="bibr">18</xref>].</p><p>A study from Saudi Arabia reported an eradication rate of 78.3% using bismuth quadruple therapy for 10 days in na&#x000ef;ve patients or those previously treated with either standard triple therapy for 14 days or sequential therapy for 10 days [<xref rid="hsr270432-bib-0019" ref-type="bibr">19</xref>]. A meta&#x02010;analysis examining <italic toggle="yes">H. pylori</italic> regimens revealed that quadruple therapy consisting of bismuth for 10&#x02013;14 days resulted in an 85% eradication rate [<xref rid="hsr270432-bib-0020" ref-type="bibr">20</xref>]. Trials conducted in Asia showed significantly higher eradication rates in individuals who received bismuth therapy as compared to trials conducted in Europe and the United States (82% vs. 74%) [<xref rid="hsr270432-bib-0021" ref-type="bibr">21</xref>, <xref rid="hsr270432-bib-0022" ref-type="bibr">22</xref>, <xref rid="hsr270432-bib-0023" ref-type="bibr">23</xref>].</p><p>Several studies conducted worldwide evaluating the efficacy of bismuth&#x02010;based quadruple therapy for <italic toggle="yes">H. pylori</italic> eradication have shown varying results, none of which were identical. In 92.7% of treatment&#x02010;na&#x000ef;ve individuals in an Italian study, <italic toggle="yes">H. pylori</italic> eradication was accomplished [<xref rid="hsr270432-bib-0012" ref-type="bibr">12</xref>]. Delchier and colleagues treated <italic toggle="yes">H. pylori</italic>&#x02010;positive patients with bismuth&#x02010;based therapy in a multicenter, open&#x02010;label, single&#x02010;arm study conducted in France, Germany, Italy, and Spain. These authors have reported similar results. The eradication rates were 93.2% to 93.8%. In contrast, a 14&#x02010;day bismuth&#x02010;containing quadruple response to therapy was observed in 50% of the Lebanese patients with peptic ulcers [<xref rid="hsr270432-bib-0024" ref-type="bibr">24</xref>, <xref rid="hsr270432-bib-0025" ref-type="bibr">25</xref>, <xref rid="hsr270432-bib-0026" ref-type="bibr">26</xref>]. The success of eliminating <italic toggle="yes">H. pylori</italic> infection is primarily dependent on <italic toggle="yes">H. pylori</italic> susceptibility to antibiotics included in the regimen. These disparate regimen results are likely attributable to the regional distribution of bacterial resistance [<xref rid="hsr270432-bib-0027" ref-type="bibr">27</xref>].</p><p>One of the most noteworthy findings of our study was that within Group I, which consisted of levofloxacin&#x02010;based triple treatment, the eradication rate varied across different treatment intervals: 6.66% for 7 days, 36.1% for 10 days, and 80% for 14 days. Levofloxacin&#x02010;based first&#x02010;line therapy has been used in clinical practice since the year 2000. The total eradication rate across seven randomized controlled trials (RCTs) was 79.05% for the levofloxacin&#x02010;based regimen [<xref rid="hsr270432-bib-0028" ref-type="bibr">28</xref>]. Other studies have reported <italic toggle="yes">H. pylori</italic> eradication rates ranging from 75% to 96% with levofloxacin&#x02010;based first&#x02010;line therapy [<xref rid="hsr270432-bib-0029" ref-type="bibr">29</xref>, <xref rid="hsr270432-bib-0030" ref-type="bibr">30</xref>, <xref rid="hsr270432-bib-0031" ref-type="bibr">31</xref>, <xref rid="hsr270432-bib-0032" ref-type="bibr">32</xref>]. The 14&#x02010;day triple therapy with omeprazole, levofloxacin (500&#x02009;mg daily), and amoxicillin had a success rate of 75% [<xref rid="hsr270432-bib-0033" ref-type="bibr">33</xref>].</p><p>In a Kosovo trial, 105 patients were randomly assigned to receive levofloxacin&#x02010;based regimens consisting of omeprazole, levofloxacin (500&#x02009;mg daily), and amoxicillin for either 7 or 10 days; and 86.2% and 93.6% of <italic toggle="yes">H. pylori</italic> infections were eradicated [<xref rid="hsr270432-bib-0034" ref-type="bibr">34</xref>]. Combining PPI, amoxicillin, and levofloxacin has been shown in previous research to be the most effective way to eliminate <italic toggle="yes">H. pylori</italic> (~90% success rate) [<xref rid="hsr270432-bib-0035" ref-type="bibr">35</xref>, <xref rid="hsr270432-bib-0036" ref-type="bibr">36</xref>].</p><p>Wu and colleagues discovered that levofloxacin&#x02010;based triple therapy had an <italic toggle="yes">H. pylori</italic> eradication rate of 67.6%, which was lower than that reported in previous studies [<xref rid="hsr270432-bib-0037" ref-type="bibr">37</xref>]. A meta&#x02010;analysis revealed significant variation in the response to triple therapy with levofloxacin. The clear causes of high heterogeneity were not apparent. The study population was the primary distinction among studies. Levofloxacin&#x02010;resistant <italic toggle="yes">H. pylori</italic> strains are becoming increasingly common worldwide, particularly in countries with a high quinolone intake. Resistance reduces the effectiveness of levofloxacin&#x02010;based regimens in eliminating <italic toggle="yes">H. pylori</italic> [<xref rid="hsr270432-bib-0038" ref-type="bibr">38</xref>]. When fluoroquinolone resistance is high, levofloxacin&#x02010;based triple therapy becomes ineffective. In Italy, the eradication rate has dropped dramatically from 75% in levofloxacin&#x02010;susceptible patients to 33.3% in patients with levofloxacin&#x02010;resistant strains [<xref rid="hsr270432-bib-0039" ref-type="bibr">39</xref>]. A prospective study in Saudi Arabia in 2015 found that <italic toggle="yes">H. pylori</italic> resistance to metronidazole, clarithromycin, amoxicillin, levofloxacin, and tetracycline was 48.5%, 23.3%, 14.8%, 11.1%, and 2.3%, respectively [<xref rid="hsr270432-bib-0040" ref-type="bibr">40</xref>]. In a trial conducted in Saudi Arabia by Alsohaibani and colleagues, levofloxacin&#x02010;based triple treatment was found to be less effective as rescue therapy (36.36%) [<xref rid="hsr270432-bib-0041" ref-type="bibr">41</xref>].</p><p>Because of increased rates of levofloxacin resistance, levofloxacin should not be used for therapy unless the <italic toggle="yes">H. pylori</italic> strain is known to be responsive to it or the population's levofloxacin resistance rate is &#x0003c;&#x02009;15% [<xref rid="hsr270432-bib-0042" ref-type="bibr">42</xref>, <xref rid="hsr270432-bib-0043" ref-type="bibr">43</xref>]. Levofloxacin&#x02010;based first&#x02010;line therapy may be a viable option for patients in places where quinolone resistance is low but clarithromycin resistance is significant [<xref rid="hsr270432-bib-0018" ref-type="bibr">18</xref>, <xref rid="hsr270432-bib-0028" ref-type="bibr">28</xref>]. When first&#x02010;line clarithromycin therapy fails, the ACG Clinical Guidelines for the Management of <italic toggle="yes">H. pylori</italic> infection recommend bismuth quadruple therapy or levofloxacin salvage regimens [<xref rid="hsr270432-bib-0003" ref-type="bibr">3</xref>].</p><p>In the current study, all patients in Group II who underwent bismuth triple therapy had a 10&#x02010;day treatment duration. In a study that examined 6 RCTs and 4763 patients, there was no significant difference in the success rates of bismuth&#x02010;containing quadruple regimens at 7, 10, or 14 days [<xref rid="hsr270432-bib-0044" ref-type="bibr">44</xref>]. There were no significant differences in efficacy between bismuth quadruple treatment regimens administered for 10 or 14 days [<xref rid="hsr270432-bib-0045" ref-type="bibr">45</xref>].</p><p>In Group I, which received levofloxacin triple therapy, there was a substantial difference in the treatment response, with a longer duration of therapy (14 days). This is supported by a study conducted in Turkey, which showed that levofloxacin triple therapy worked much better when administered for a longer period as a first&#x02010;line treatment (72% with a 14&#x02010;day regimen vs. 34% with a 7&#x02010;day regimen) [<xref rid="hsr270432-bib-0046" ref-type="bibr">46</xref>]. This is also consistent with guidelines that prescribe longer (14 days) treatments with all antibiotic regimens for <italic toggle="yes">H. pylori</italic> [<xref rid="hsr270432-bib-0047" ref-type="bibr">47</xref>, <xref rid="hsr270432-bib-0048" ref-type="bibr">48</xref>].</p><p>We found no statistical differences in eradication rates between the two regimens in patients aged &#x02265;&#x02009;60 years and non&#x02010;Saudi patients. Previous studies have shown that the eradication rate of <italic toggle="yes">H. pylori</italic> treatment regimens is not related to age [<xref rid="hsr270432-bib-0049" ref-type="bibr">49</xref>, <xref rid="hsr270432-bib-0050" ref-type="bibr">50</xref>]. While others have revealed that age influences <italic toggle="yes">H. pylori</italic> eradication in both developed and developing nations [<xref rid="hsr270432-bib-0051" ref-type="bibr">51</xref>, <xref rid="hsr270432-bib-0052" ref-type="bibr">52</xref>], and the results of a study conducted in Pakistan indicated that there has been a substantial rise in the incidence of failure among both young and elderly individuals. Conversely, the middle&#x02010;aged group showed a higher eradication [<xref rid="hsr270432-bib-0053" ref-type="bibr">53</xref>].</p><p>In addition, there was no statistical difference in the eradication rate across patients for either regimen when omeprazole was used. In contrast, Vergara and colleagues conducted a MEDLINE search for a meta&#x02010;analysis of 14 studies comparing the efficacy of various PPIs in triple therapy, which yielded comparable results [<xref rid="hsr270432-bib-0054" ref-type="bibr">54</xref>]. However, another study discovered that esomeprazole and rabeprazole had a slight advantage over first&#x02010;generation PPIs in terms of overall <italic toggle="yes">H. pylori</italic> eradication rates [<xref rid="hsr270432-bib-0055" ref-type="bibr">55</xref>].</p><p>Although triple therapy based on traditional PPIs is successful, prolonged acid suppression treatments are attracting increasing attention. New regimens for <italic toggle="yes">H. pylori</italic> eradication include potassium&#x02010;competitive acid blocker (P&#x02010;CAB) triple and dual treatment. According to a recent meta&#x02010;analysis and systematic review, triple therapy using vonoprazan, an acid blocker that competes with potassium, worked better than triple therapy using traditional PPIs. This makes it an even better first&#x02010;line treatment [<xref rid="hsr270432-bib-0056" ref-type="bibr">56</xref>].</p><p>The most interesting finding in our study was that the 14&#x02010;day levofloxacin&#x02010;based triple therapy achieved an <italic toggle="yes">H. pylori</italic> eradication rate comparable to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy. According to a study from Turkey, standard bismuth&#x02010;based quadruple therapy was better at eliminating <italic toggle="yes">H. pylori</italic> infections (&#x0003e;&#x02009;90%) than levofloxacin&#x02010;containing triple therapy (79.2%) [<xref rid="hsr270432-bib-0057" ref-type="bibr">57</xref>]. Another study from Vietnam concluded that the initial four&#x02010;drug regimen with bismuth is more effective at eradicating <italic toggle="yes">H. pylori</italic> than three&#x02010;drug treatment with levofloxacin as the first&#x02010;line treatment; however, the patient's compliance rate was lower than that of the levofloxacin&#x02010;based three&#x02010;drug regimen [<xref rid="hsr270432-bib-0018" ref-type="bibr">18</xref>]. This finding highlights that the longer, but one drug less, triple therapy may be more readily accepted by patients, considering the associated treatment costs and potential side effects.</p><p>To optimally treat <italic toggle="yes">H. pylori</italic> infections, local antibiotic resistance and eradication patterns must be carefully considered. Thus, quadruple therapy may play a larger role in the eradication of <italic toggle="yes">H. pylori</italic> [<xref rid="hsr270432-bib-0047" ref-type="bibr">47</xref>]. Owing to the high prevalence of resistance to clarithromycin and metronidazole, the Saudi <italic toggle="yes">H. pylori</italic> Working Group concluded that antimicrobial susceptibility testing is necessary before administering conventional triple therapy for 10&#x02013;14 days to treat <italic toggle="yes">H. pylori</italic>. According to the available data, bismuth&#x02010;based quadruple treatment for 10&#x02013;14 days is the most effective first&#x02010; and second&#x02010;line therapy in Saudi Arabia [<xref rid="hsr270432-bib-0058" ref-type="bibr">58</xref>].</p><p>A limitation of the present study was the lack of regional antibiotic resistance patterns. Because antibiotic resistance rates vary among regions, the findings of this study cannot be applied internationally. Other limitations include its retrospective nature with the small number of patients in each group. Other restrictions included the absence of information regarding smoking and alcohol consumption, adverse effects of the two regimens, and clinical presentation or endoscopic findings of our patients.</p></sec><sec sec-type="conclusions" id="hsr270432-sec-0160"><label>5</label><title>Conclusion</title><p>Standard bismuth&#x02010;based quadruple therapy for <italic toggle="yes">H. pylori</italic> has achieved satisfactory eradication rates. Levofloxacin&#x02010;based triple treatment has a lower efficacy in <italic toggle="yes">H. pylori</italic> eradication compared to bismuth&#x02010;based quadruple therapy when administered for short periods (7 or 10 days). The optimal duration of levofloxacin&#x02010;based triple therapy was 14 days, resulting in a higher H. pylori eradication rate equivalent to that of the 10&#x02010;day bismuth&#x02010;based quadruple therapy. This highlights that, for successful <italic toggle="yes">H. pylori</italic> eradication, treatment tactics must be tailored to local antibiotic resistance trends. Future large&#x02010;scale randomized studies are warranted to determine the most effective treatment method for <italic toggle="yes">H. pylori</italic> infection in Saudi Arabia.</p></sec><sec id="hsr270432-sec-0170"><title>Author Contributions</title><p>
<bold>Abdulrhman Khaled Al Abdulqader:</bold> conceptualization, supervision. <bold>Turki Abdullah Alamri:</bold> visualization. <bold>Mahdi Abdullah Alhamad:</bold> data curation. <bold>Somaia Shehab El&#x02010;Deen:</bold> analysis of the results, supervision, writing &#x02013; original draft. <bold>Abdallah Essa:</bold> methodology, writing &#x02013; review and editing. <bold>Raed Abdullah Alfayez:</bold> data curation. <bold>Baqer Mohammed Albaqshi:</bold> data curation. <bold>Adnan Salah Almajed:</bold> data curation. <bold>Mohammed Yousef Alhassan:</bold> data curation. <bold>Ali Essa:</bold> writing &#x02013; original draft, writing &#x02013; review and editing. <bold>Ahmed Abdullah Albadrani:</bold> visualization. <bold>Omar Alomair:</bold> methodology. <bold>Bashaeer Abdullh Al Jalal:</bold> writing &#x02013; review and editing. <bold>Mohammed Yousef Almulhim:</bold> methodology. <bold>Abdullah Alotaibi:</bold> visualization. <bold>Ehab Darwish:</bold> writing &#x02013; original draft, supervision. All authors have read and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement" id="hsr270432-sec-0190"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="hsr270432-sec-0220"><title>Transparency Statement</title><p>The lead author Abdulrhman Khaled Al Abdulqader affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.</p></sec></body><back><ack id="hsr270432-sec-0180"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="hsr270432-sec-0210"><title>Data Availability Statement</title><p>The data of this study are available from the first author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="hsr270432-bibl-0001"><title>References</title><ref id="hsr270432-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="hsr270432-cit-0001">
<string-name>
<given-names>J. K. Y.</given-names>
<surname>Hooi</surname>
</string-name>, <string-name>
<given-names>W. Y.</given-names>
<surname>Lai</surname>
</string-name>, <string-name>
<given-names>W. K.</given-names>
<surname>Ng</surname>
</string-name>, et al., &#x0201c;<article-title>Global Prevalence of <italic toggle="yes">Helicobacter pylori</italic> Infection: Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>153</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>420</fpage>&#x02013;<lpage>429</lpage>.<pub-id pub-id-type="pmid">28456631</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hsr270432-cit-0002">
<string-name>
<given-names>J. S.</given-names>
<surname>Muhammad</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Sugiyama</surname>
</string-name>, and <string-name>
<given-names>S. F.</given-names>
<surname>Zaidi</surname>
</string-name>, &#x0201c;<article-title>Gastric Pathophysiological Ins and Outs of <italic toggle="yes">Helicobacter pylori</italic>: A Review</article-title>,&#x0201d; <source>Journal of the Pakistan Medical Association</source>
<volume>63</volume>, no. <issue>12</issue> (<year>2013</year>): <fpage>1528</fpage>&#x02013;<lpage>1533</lpage>.<pub-id pub-id-type="pmid">24397100</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hsr270432-cit-0003">
<string-name>
<given-names>W. D.</given-names>
<surname>Chey</surname>
</string-name>, <string-name>
<given-names>G. I.</given-names>
<surname>Leontiadis</surname>
</string-name>, <string-name>
<given-names>C. W.</given-names>
<surname>Howden</surname>
</string-name>, and <string-name>
<given-names>S. F.</given-names>
<surname>Moss</surname>
</string-name>, &#x0201c;<article-title>ACG Clinical Guideline: Treatment of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>American Journal of Gastroenterology</source>
<volume>112</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>212</fpage>&#x02013;<lpage>239</lpage>.<pub-id pub-id-type="pmid">28071659</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="hsr270432-cit-0004">
<string-name>
<given-names>D.</given-names>
<surname>Graham</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Lu</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Shiotani</surname>
</string-name>, &#x0201c;<article-title>Failure of Optimized Dual Proton Pump Inhibitor Amoxicillin Therapy: What Now?</article-title>,&#x0201d; <source>Saudi Journal of Gastroenterology</source>
<volume>23</volume>, no. <issue>5</issue> (<year>2017</year>): <fpage>265</fpage>.<pub-id pub-id-type="pmid">28937019</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="hsr270432-cit-0005">
<string-name>
<given-names>E. M.</given-names>
<surname>Eed</surname>
</string-name>, <string-name>
<given-names>Y. A.</given-names>
<surname>Hawash</surname>
</string-name>, <string-name>
<given-names>A. S.</given-names>
<surname>Khalifa</surname>
</string-name>, et al., &#x0201c;<article-title>Molecular Diagnosis of <italic toggle="yes">Helicobacter pylori</italic> Antibiotic Resistance in the Taif Region, Saudi Arabia</article-title>,&#x0201d; <source>Microbiology and Immunology</source>
<volume>63</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>199</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">31045263</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="hsr270432-cit-0006">
<string-name>
<given-names>F.</given-names>
<surname>Alsohaibani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Peedikayil</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Alshahrani</surname>
</string-name>, et al., &#x0201c;<article-title>Practice Guidelines for the Management of <italic toggle="yes">Helicobacter pylori</italic> Infection: The Saudi <italic toggle="yes">H. pylori</italic> Working Group Recommendations</article-title>,&#x0201d; <source>Saudi Journal of Gastroenterology</source>
<volume>29</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>326</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">36204804</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="hsr270432-cit-0007">
<string-name>
<given-names>T.</given-names>
<surname>Rokkas</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Sechopoulos</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Robotis</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Pistiolas</surname>
</string-name>, &#x0201c;<article-title>Triple Levofloxacin&#x02010;Based Rescue Therapy Is an Accepted Empirical Third&#x02010;Line Treatment</article-title>,&#x0201d; <source>American Journal of Gastroenterology</source>
<volume>101</volume>, no. <issue>8</issue> (<year>2006</year>): <fpage>1938</fpage>.<pub-id pub-id-type="pmid">16928256</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hsr270432-cit-0008">
<string-name>
<given-names>J. P.</given-names>
<surname>Gisbert</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Gisbert</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Marcos</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Moreno&#x02010;Otero</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Pajares</surname>
</string-name>, &#x0201c;<article-title>Third&#x02010;Line Rescue Therapy With Levofloxacin Is More Effective Than Rifabutin Rescue Regimen After Two <italic toggle="yes">Helicobacter pylori</italic> Treatment Failures</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>24</volume>, no. <issue>10</issue> (<year>2006</year>): <fpage>1469</fpage>&#x02013;<lpage>1474</lpage>.<pub-id pub-id-type="pmid">17032282</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hsr270432-cit-0009">
<string-name>
<given-names>J. P.</given-names>
<surname>Gisbert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Castro&#x02010;Fern&#x000e1;ndez</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Bermejo</surname>
</string-name>, et al., &#x0201c;<article-title>Third&#x02010;Line Rescue Therapy With Levofloxacin After Two <italic toggle="yes">H. pylori</italic> Treatment Failures</article-title>,&#x0201d; <source>American Journal of Gastroenterology</source>
<volume>101</volume>, no. <issue>2</issue> (<year>2006</year>): <fpage>243</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">16454825</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hsr270432-cit-0010">
<string-name>
<given-names>L. G.</given-names>
<surname>Coelho</surname>
</string-name>, <string-name>
<given-names>L. D.</given-names>
<surname>Moretzsohn</surname>
</string-name>, <string-name>
<given-names>W. L.</given-names>
<surname>Vieira</surname>
</string-name>, et al., &#x0201c;<article-title>New Once&#x02010;Daily, Highly Effective Rescue Triple Therapy After Multiple <italic toggle="yes">Helicobacter pylori</italic> Treatment Failures: A Pilot Study</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>21</volume>, no. <issue>6</issue> (<year>2005</year>): <fpage>783</fpage>&#x02013;<lpage>787</lpage>.<pub-id pub-id-type="pmid">15771765</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="hsr270432-cit-0011">
<string-name>
<given-names>G.</given-names>
<surname>Cammarota</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Cianci</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Cannizzaro</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy of Two One&#x02010;Week Rabeprazole/Levofloxacin&#x02010;Based Triple Therapies for <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>14</volume>, no. <issue>10</issue> (<year>2000</year>): <fpage>1339</fpage>&#x02013;<lpage>1343</lpage>.<pub-id pub-id-type="pmid">11012480</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hsr270432-cit-0012">
<string-name>
<given-names>E. C.</given-names>
<surname>Nista</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Candelli</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Zocco</surname>
</string-name>, et al., &#x0201c;<article-title>Levofloxacin&#x02010;Based Triple Therapy in First&#x02010;Line Treatment for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>American Journal of Gastroenterology</source>
<volume>101</volume>, no. <issue>9</issue> (<year>2006</year>): <fpage>1985</fpage>&#x02013;<lpage>1990</lpage>.<pub-id pub-id-type="pmid">16968503</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hsr270432-cit-0013">
<string-name>
<given-names>J. P.</given-names>
<surname>Gisbert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fern&#x000e1;ndez&#x02010;Bermejo</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Molina&#x02010;Infante</surname>
</string-name>, et al., &#x0201c;<article-title>First&#x02010;Line Triple Therapy With Levofloxacin for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>26</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>495</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">17635384</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="hsr270432-cit-0014">
<string-name>
<given-names>Y. K.</given-names>
<surname>Yee</surname>
</string-name>, <string-name>
<given-names>T. K.</given-names>
<surname>Cheung</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Chu</surname>
</string-name>, et al., &#x0201c;<article-title>Clinical Trial: Levofloxacin&#x02010;Based Quadruple Therapy Was Inferior to Traditional Quadruple Therapy in the Treatment of Resistant <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>26</volume>, no. <issue>7</issue> (<year>2007</year>): <fpage>1063</fpage>&#x02013;<lpage>1067</lpage>.<pub-id pub-id-type="pmid">17877513</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hsr270432-cit-0015">
<string-name>
<given-names>J.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hao</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>Efficacy of 1st&#x02010;Line Bismuth&#x02010;Containing Quadruple Therapies With Levofloxacin or Clarithromycin for the Eradication of <italic toggle="yes">Helicobacter pylori</italic> Infection: A 1&#x02010;Week, Open&#x02010;Label, Randomized Trial</article-title>,&#x0201d; <source>Medicine</source>
<volume>96</volume>, no. <issue>7</issue> (<year>2017</year>): <elocation-id>e5859</elocation-id>.<pub-id pub-id-type="pmid">28207505</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="hsr270432-cit-0016">
<string-name>
<given-names>P.</given-names>
<surname>Correa</surname>
</string-name>, &#x0201c;<article-title>
<italic toggle="yes">Helicobacter pylori</italic> as a Pathogen and Carcinogen</article-title>,&#x0201d; <source>Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society</source>
<volume>48 Suppl 4</volume> (<year>1997</year>): <fpage>19</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">9440052</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hsr270432-cit-0017">
<string-name>
<given-names>E.</given-names>
<surname>Kahramano&#x0011f;lu Aksoy</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Pirin&#x000e7;ci Sapmaz</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>G&#x000f6;kta&#x0015f;</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Uzman</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Nazl&#x00131;g&#x000fc;l</surname>
</string-name>, &#x0201c;<article-title>Comparison of <italic toggle="yes">Helicobacter pylori</italic> Eradication Rates of 2&#x02010;Week Levofloxacin&#x02010;Containing Triple Therapy, Levofloxacin&#x02010;Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First&#x02010;Line Regimen</article-title>,&#x0201d; <source>Medical Principles and Practice</source>
<volume>26</volume>, no. <issue>6</issue> (<year>2018</year>): <fpage>523</fpage>&#x02013;<lpage>529</lpage>.</mixed-citation></ref><ref id="hsr270432-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="hsr270432-cit-0018">
<string-name>
<given-names>T. T. K.</given-names>
<surname>Tuong</surname>
</string-name>, <string-name>
<given-names>H. Q.</given-names>
<surname>Huy</surname>
</string-name>, <string-name>
<given-names>T. N. D.</given-names>
<surname>Hong</surname>
</string-name>, <string-name>
<given-names>N. T. A.</given-names>
<surname>&#x00110;ao</surname>
</string-name>, and <string-name>
<given-names>N. T. T.</given-names>
<surname>Quyt</surname>
</string-name>, &#x0201c;<article-title>Bismuth Quadruple Therapy Versus Levofloxacin Triple Therapy for First&#x02010;Line <italic toggle="yes">Helicobacter pylori</italic> Eradication Treatment: Multicenter Study</article-title>,&#x0201d; <source>Medical Science</source>
<volume>24</volume>, no. <issue>104</issue> (<year>2020</year>): <fpage>2246</fpage>&#x02013;<lpage>2250</lpage>.</mixed-citation></ref><ref id="hsr270432-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="hsr270432-cit-0019">
<string-name>
<given-names>F.</given-names>
<surname>Alsohaibani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Alquaiz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Alkahtani</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy of a Bismuth&#x02010;Based Quadruple Therapy Regimen for <italic toggle="yes">Helicobacter pylori</italic> Eradication in Saudi Arabia</article-title>,&#x0201d; <source>Saudi Journal of Gastroenterology</source>
<volume>26</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>84</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">32295933</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hsr270432-cit-0020">
<string-name>
<given-names>B.&#x02010;Z.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D. E.</given-names>
<surname>Threapleton</surname>
</string-name>, <string-name>
<given-names>J.&#x02010;Y.</given-names>
<surname>Wang</surname>
</string-name>, et al., &#x0201c;<article-title>Comparative Effectiveness and Tolerance of Treatments for <italic toggle="yes">Helicobacter</italic>: Systematic Review and Network Meta&#x02010;Analysis</article-title>,&#x0201d; <source>BMJ</source>
<volume>351</volume> (<year>2015</year>): <fpage>4052</fpage>.</mixed-citation></ref><ref id="hsr270432-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hsr270432-cit-0021">
<string-name>
<given-names>N.</given-names>
<surname>Magaret</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Burm</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Faigel</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Kelly</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Peterson</surname>
</string-name>, and <string-name>
<given-names>M. B.</given-names>
<surname>Fennerty</surname>
</string-name>, &#x0201c;<article-title>A Randomized Trial of Lansoprazole, Amoxycillin, and Clarithromycin Versus Lansoprazole, Bismuth, Metronidazole and Tetracycline in the Retreatment of Patients Failing Initial <italic toggle="yes">Helicobacter pylori</italic> Therapy</article-title>,&#x0201d; <source>Digestive Diseases</source>
<volume>19</volume>, no. <issue>2</issue> (<year>2001</year>): <fpage>174</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">11549829</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hsr270432-cit-0022">
<string-name>
<given-names>S.</given-names>
<surname>Miehlke</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Kirsch</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Schneider&#x02010;Brachert</surname>
</string-name>, et al., &#x0201c;<article-title>A Prospective, Randomized Study of Quadruple Therapy and High&#x02010;Dose Dual Therapy for Treatment of <italic toggle="yes">Helicobacter pylori</italic> Resistant to Both Metronidazole and Clarithromycin</article-title>,&#x0201d; <source>Helicobacter</source>
<volume>8</volume>, no. <issue>4</issue> (<year>2003</year>): <fpage>310</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">12950604</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="hsr270432-cit-0023">
<string-name>
<given-names>Z.</given-names>
<surname>Cao</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Zhang</surname>
</string-name>, et al., &#x0201c;<article-title>Fourteen&#x02010;Day Optimized Levofloxacin&#x02010;Based Therapy Versus Classical Quadruple Therapy for <italic toggle="yes">Helicobacter pylori</italic> Treatment Failures: A Randomized Clinical Trial</article-title>,&#x0201d; <source>Scandinavian Journal of Gastroenterology</source>
<volume>50</volume>, no. <issue>10</issue> (<year>2015</year>): <fpage>1185</fpage>&#x02013;<lpage>1190</lpage>.<pub-id pub-id-type="pmid">25881966</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="hsr270432-cit-0024">
<string-name>
<given-names>A.</given-names>
<surname>Tursi</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Di Mario</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Franceschi</surname>
</string-name>, et al., &#x0201c;<article-title>New Bismuth&#x02010;Containing Quadruple Therapy in Patients Infected With <italic toggle="yes">Helicobacter pylori</italic>: A First Italian Experience in Clinical Practice</article-title>,&#x0201d; <source>Helicobacter</source>
<volume>22</volume>, no. <issue>3</issue> (<year>2017</year>): <elocation-id>e12371</elocation-id>.</mixed-citation></ref><ref id="hsr270432-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hsr270432-cit-0025">
<string-name>
<given-names>J. C.</given-names>
<surname>Delchier</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Malfertheiner</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Thieroff&#x02010;Ekerdt</surname>
</string-name>, &#x0201c;<article-title>Use of a Combination Formulation of Bismuth, Metronidazole and Tetracycline With Omeprazole as a Rescue Therapy for Eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>40</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>171</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">24863854</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="hsr270432-cit-0026">
<string-name>
<given-names>M.</given-names>
<surname>Tarhini</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fayyad&#x02010;Kazan</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Fayyad&#x02010;Kazan</surname>
</string-name>, et al., &#x0201c;<article-title>First&#x02010;Line Treatment of <italic toggle="yes">Helicobacter pylori</italic> in Lebanon: Comparison of Bismuth&#x02010;Containing Quadruple Therapy Versus 14&#x02010;Days Sequential Therapy</article-title>,&#x0201d; <source>Microbial Pathogenesis</source>
<volume>117</volume> (<year>2018</year>): <fpage>23</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">29428426</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="hsr270432-cit-0027">
<string-name>
<given-names>X.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zheng</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy of Bismuth&#x02010;Containing Quadruple Therapies for Clarithromycin&#x02010;, Metronidazole&#x02010;, and Fluoroquinolone&#x02010;Resistant <italic toggle="yes">Helicobacter pylori</italic> Infections in a Prospective Study</article-title>,&#x0201d; <source>Clinical Gastroenterology and Hepatology</source>
<volume>11</volume>, no. <issue>7</issue> (<year>2013</year>): <fpage>802</fpage>&#x02013;<lpage>807.e1</lpage>.<pub-id pub-id-type="pmid">23376004</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="hsr270432-cit-0028">
<string-name>
<given-names>M. C.</given-names>
<surname>Peedikayil</surname>
</string-name>, <string-name>
<given-names>F. I.</given-names>
<surname>AlSohaibani</surname>
</string-name>, and <string-name>
<given-names>A. H.</given-names>
<surname>Alkhenizan</surname>
</string-name>, &#x0201c;<article-title>Levofloxacin&#x02010;Based First&#x02010;Line Therapy Versus Standard First&#x02010;Line Therapy for <italic toggle="yes">Helicobacter pylori</italic> Eradication: Meta&#x02010;Analysis of Randomized Controlled Trials</article-title>,&#x0201d; <source>PLoS One</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2014</year>): <elocation-id>e85620</elocation-id>.<pub-id pub-id-type="pmid">24465624</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="hsr270432-cit-0029">
<string-name>
<given-names>G.</given-names>
<surname>Cammarota</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Cianci</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Cannizzaro</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy of Two One&#x02010;Week Rabeprazole/Levofloxacin&#x02010;Based Triple Therapies for <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>14</volume>, no. <issue>10</issue> (<year>2000</year>): <fpage>1339</fpage>&#x02013;<lpage>1343</lpage>.<pub-id pub-id-type="pmid">11012480</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="hsr270432-cit-0030">
<string-name>
<given-names>S.</given-names>
<surname>Di Caro</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Zocco</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Cremonini</surname>
</string-name>, et al., &#x0201c;<article-title>Levofloxacin Based Regimens for the Eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>European Journal of Gastroenterology &#x00026; Hepatology</source>
<volume>14</volume>, no. <issue>12</issue> (<year>2002</year>): <fpage>1309</fpage>&#x02013;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">12468950</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="hsr270432-cit-0031">
<string-name>
<given-names>M.</given-names>
<surname>Castro&#x02010;Fern&#x000e1;ndez</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Lamas</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>P&#x000e9;rez&#x02010;Pastor</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy of Triple Therapy With a Proton Pump Inhibitor, Levofloxacin, and Amoxicillin as First&#x02010;Line Treatment to Eradicate <italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>Revista Espanola de Enfermedades Digestivas</source>
<volume>101</volume>, no. <issue>6</issue> (<year>2009</year>): <fpage>395</fpage>.<pub-id pub-id-type="pmid">19630462</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="hsr270432-cit-0032">
<string-name>
<given-names>R.</given-names>
<surname>Schrauwen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Janssen</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>De Boer</surname>
</string-name>. &#x0201c;<article-title>Seven&#x02010;Day PPI&#x02010;Triple Therapy With Levofloxacin Is Very Effective for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>The Netherlands Journal of Medicine</source>
<volume>67</volume>, no. <issue>3</issue> (<year>2009</year>): <fpage>96</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">19307680</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="hsr270432-cit-0033">
<string-name>
<given-names>A. A.</given-names>
<surname>Haji&#x02010;Aghamohammadi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bastani</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Miroliaee</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Oveisi</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Safarnezhad</surname>
</string-name>, &#x0201c;<article-title>Comparison of Levofloxacin Versus Clarithromycin Efficacy in the Eradication of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Caspian Journal of Internal Medicine</source>
<volume>7</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>267</fpage>.<pub-id pub-id-type="pmid">27999644</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="hsr270432-cit-0034">
<string-name>
<given-names>S.</given-names>
<surname>Telaku</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Manxhuka&#x02010;Kerliu</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Kraja</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Qirjako</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Prifti</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Fejza</surname>
</string-name>, &#x0201c;<article-title>The Efficacy of Levofloxacin&#x02010;Based Triple Therapy for First&#x02010;Line <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>Medical Archives</source>
<volume>67</volume> (<year>2013</year>): <fpage>348</fpage>.<pub-id pub-id-type="pmid">24601169</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="hsr270432-cit-0035">
<string-name>
<given-names>J.</given-names>
<surname>Gisbert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fernandez&#x02010;Bermejo</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Molina&#x02010;Infante</surname>
</string-name>, et al., &#x0201c;<article-title>First&#x02010;Line Triple Therapy With Levofloxacin for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>26</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>495</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">17635384</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="hsr270432-cit-0036">
<string-name>
<given-names>A.</given-names>
<surname>Rispo</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Di Girolamo</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Cozzolino</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Bozzi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Morante</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Pasquale</surname>
</string-name>, &#x0201c;<article-title>Levofloxacin in First&#x02010;Line Treatment of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Helicobacter</source>
<volume>12</volume>, no. <issue>4</issue> (<year>2007</year>): <fpage>364</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">17669111</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="hsr270432-cit-0037">
<string-name>
<given-names>T. S.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>P. I.</given-names>
<surname>Hsu</surname>
</string-name>, <string-name>
<given-names>C. H.</given-names>
<surname>Kuo</surname>
</string-name>, et al., &#x0201c;<article-title>Comparison of 10&#x02010;Day Levofloxacin Bismuth&#x02010;Based Quadruple Therapy and Levofloxacin&#x02010;Based Triple Therapy for <italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>Journal of Digestive Diseases</source>
<volume>18</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>537</fpage>&#x02013;<lpage>542</lpage>.<pub-id pub-id-type="pmid">28644575</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="hsr270432-cit-0038">
<string-name>
<given-names>P. Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>M. S.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>C. Y.</given-names>
<surname>Chen</surname>
</string-name>, et al., &#x0201c;<article-title>Systematic Review With Meta&#x02010;Analysis: The Efficacy of Levofloxacin Triple Therapy as the First&#x02010; or Second&#x02010;Line Treatments of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Alimentary Pharmacology and Therapeutics</source>
<volume>44</volume>, no. <issue>5</issue> (<year>2016</year>): <fpage>427</fpage>&#x02013;<lpage>437</lpage>.<pub-id pub-id-type="pmid">27363687</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="hsr270432-cit-0039">
<string-name>
<given-names>F.</given-names>
<surname>Perna</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Zullo</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Ricci</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Hassan</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Morini</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Vaira</surname>
</string-name>, &#x0201c;<article-title>Levofloxacin&#x02010;Based Triple Therapy for <italic toggle="yes">Helicobacter pylori</italic> Re&#x02010;Treatment: Role of Bacterial Resistance</article-title>,&#x0201d; <source>Digestive and Liver Disease</source>
<volume>39</volume>, no. <issue>11</issue> (<year>2007</year>): <fpage>1001</fpage>&#x02013;<lpage>1005</lpage>.<pub-id pub-id-type="pmid">17889627</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="hsr270432-cit-0040">
<string-name>
<given-names>F.</given-names>
<surname>Alsohaibani</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Al Ashgar</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Al Kahtani</surname>
</string-name>, et al., &#x0201c;<article-title>Prospective Trial in Saudi Arabia Comparing the 14&#x02010;Day Standard Triple Therapy With the 10&#x02010;Day Sequential Therapy for Treatment of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Saudi Journal of Gastroenterology</source>
<volume>21</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>220</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">26228365</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="hsr270432-cit-0041">
<string-name>
<given-names>F. I.</given-names>
<surname>Alsohaibani</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Alharfi</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Almadi</surname>
</string-name>, &#x0201c;<article-title>Efficacy of Levofloxacin&#x02010;Doxycycline&#x02010;Based Rescue Therapy for <italic toggle="yes">Helicobacter pylori</italic> Eradication: A Prospective Open&#x02010;Label Trial in Saudi Arabia</article-title>,&#x0201d; <source>Journal of Health Specialties</source>
<volume>5</volume>, no. <issue>3</issue> (<year>2017</year>): <fpage>155</fpage>&#x02013;<lpage>161</lpage>.</mixed-citation></ref><ref id="hsr270432-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="hsr270432-cit-0042">
<string-name>
<given-names>A.</given-names>
<surname>Savoldi</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Carrara</surname>
</string-name>, <string-name>
<given-names>D. Y.</given-names>
<surname>Graham</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Conti</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Tacconelli</surname>
</string-name>, &#x0201c;<article-title>Prevalence of Antibiotic Resistance in <italic toggle="yes">Helicobacter pylori</italic>: A Systematic Review and Meta&#x02010;Analysis in World Health Organization Regions</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>155</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>1372</fpage>&#x02013;<lpage>82.e17</lpage>.<pub-id pub-id-type="pmid">29990487</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="hsr270432-cit-0043">
<string-name>
<given-names>S. C.</given-names>
<surname>Shah</surname>
</string-name>, <string-name>
<given-names>P. G.</given-names>
<surname>Iyer</surname>
</string-name>, and <string-name>
<given-names>S. F.</given-names>
<surname>Moss</surname>
</string-name>, &#x0201c;<article-title>AGA Clinical Practice Update on the Management of Refractory <italic toggle="yes">Helicobacter pylori</italic> Infection: Expert Review</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>160</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>1831</fpage>&#x02013;<lpage>1841</lpage>.<pub-id pub-id-type="pmid">33524402</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="hsr270432-cit-0044">
<string-name>
<given-names>Y.</given-names>
<surname>Yuan</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Ford</surname>
</string-name>, <string-name>
<given-names>K. J.</given-names>
<surname>Khan</surname>
</string-name>, et al, &#x0201c;<article-title>Optimum Duration of Regimens for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>Cochrane Database of Systematic Reviews</source> no. <issue>12</issue> (<year>2013</year>): <elocation-id>CD008337</elocation-id>, <pub-id pub-id-type="doi">10.1002/14651858.CD008337.pub2</pub-id>.<pub-id pub-id-type="pmid">24338763</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="hsr270432-cit-0045">
<string-name>
<given-names>L.</given-names>
<surname>Fischbach</surname>
</string-name> and <string-name>
<given-names>E.</given-names>
<surname>Evans</surname>
</string-name>, &#x0201c;<article-title>Meta&#x02010;Analysis: The Effect of Antibiotic Resistance Status on the Efficacy of Triple and Quadruple First&#x02010;Line Therapies for <italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>26</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>343</fpage>&#x02013;<lpage>357</lpage>.<pub-id pub-id-type="pmid">17635369</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="hsr270432-cit-0046">
<string-name>
<given-names>C. N.</given-names>
<surname>Ercin</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Uygun</surname>
</string-name>, <string-name>
<given-names>A. B.</given-names>
<surname>Toros</surname>
</string-name>, et al., &#x0201c;<article-title>Comparison of 7&#x02010;and 14&#x02010;Day First&#x02010;Line Therapies Including Levofloxacin in Patients With <italic toggle="yes">Helicobacter pylori</italic> Positive Non&#x02010;Ulcer Dyspepsia</article-title>,&#x0201d; <source>Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology</source>
<volume>21</volume>, no. <issue>1</issue> (<year>2010</year>): <fpage>12</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">20533106</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="hsr270432-cit-0047">
<string-name>
<given-names>C. A.</given-names>
<surname>Fallone</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Chiba</surname>
</string-name>, <string-name>
<given-names>S. V.</given-names>
<surname>van Zanten</surname>
</string-name>, et al., &#x0201c;<article-title>The Toronto Consensus for the Treatment of <italic toggle="yes">Helicobacter pylori</italic> Infection in Adults</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>151</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>51</fpage>&#x02013;<lpage>69.e14</lpage>.<pub-id pub-id-type="pmid">27102658</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="hsr270432-cit-0048">
<string-name>
<given-names>P.</given-names>
<surname>Malfertheiner</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Megraud</surname>
</string-name>, <string-name>
<given-names>C. A.</given-names>
<surname>O'Morain</surname>
</string-name>, et al., &#x0201c;<article-title>Management of <italic toggle="yes">Helicobacter pylori</italic> Infection&#x02014;The Maastricht IV/Florence Consensus Report</article-title>,&#x0201d; <source>Gut</source>
<volume>61</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>646</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">22491499</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="hsr270432-cit-0049">
<string-name>
<given-names>M.</given-names>
<surname>Seyyedmajidi</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Abbasi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Seyedmajidi</surname>
</string-name>, et al., &#x0201c;<article-title>Levofloxacin&#x02010;Containing Triple Therapy Versus Bismuth&#x02010;Based Quadruple Therapy as Regimens for Second Line Anti&#x02010;<italic toggle="yes">Helicobacter pylori</italic>
</article-title>,&#x0201d; <source>Caspian Journal of Internal Medicine</source>
<volume>10</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>211</fpage>.<pub-id pub-id-type="pmid">31363400</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="hsr270432-cit-0050">
<string-name>
<given-names>M.</given-names>
<surname>Moradniani</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Mirbeik&#x02010;Sabzevari</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jaferian</surname>
</string-name>, et al., &#x0201c;<article-title>Levofloxacin Based vs Clarithromycin Based Sequential Therapy in <italic toggle="yes">Helicobacter pylori</italic> Eradication; A Randomized Clinical Trial</article-title>,&#x0201d; <source>Gastroenterology and Hepatology From Bed to Bench</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>19</fpage>.<pub-id pub-id-type="pmid">29564061</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="hsr270432-cit-0051">
<string-name>
<given-names>C.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Luo</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Chi</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Liu</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Xie</surname>
</string-name>. &#x0201c;<article-title>
<italic toggle="yes">Helicobacter pylori</italic> Eradication Failure in Patients Don't Receive Antibiotics With High Resistance and Have Good Compliance: A Retrospective Study</article-title>,&#x0201d; <source>Research Square</source> (<year>2022</year>), <pub-id pub-id-type="doi">10.21203/rs.3.rs-1280572/v1</pub-id>.</mixed-citation></ref><ref id="hsr270432-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="hsr270432-cit-0052">
<string-name>
<given-names>J. H.</given-names>
<surname>Lim</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>S. T.</given-names>
<surname>Lee</surname>
</string-name>, et al., &#x0201c;<article-title>Moxifloxacin&#x02010;Containing Triple Therapy After Non&#x02010;Bismuth Quadruple Therapy Failure for <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>World Journal of Gastroenterology</source>
<volume>21</volume>, no. <issue>46</issue> (<year>2015</year>): <elocation-id>13124</elocation-id>.<pub-id pub-id-type="pmid">26673999</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="hsr270432-cit-0053">
<string-name>
<given-names>S.</given-names>
<surname>Khadim</surname>
</string-name>, <string-name>
<given-names>I. N.</given-names>
<surname>Muhammad</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Alam</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Usman</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Rehman</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Haider</surname>
</string-name>, &#x0201c;<article-title>Predictors of Successful First&#x02010;Line <italic toggle="yes">Helicobacter pylori</italic> Eradication With Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors</article-title>,&#x0201d; <source>Antibiotics</source>
<volume>13</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>211</fpage>.<pub-id pub-id-type="pmid">38534646</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="hsr270432-cit-0054">
<string-name>
<given-names>M.</given-names>
<surname>Vergara</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Vallve</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Gisbert</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Calvet</surname>
</string-name>, &#x0201c;<article-title>Meta&#x02010;Analysis: Comparative Efficacy of Different Proton&#x02010;Pump Inhibitors in Triple Therapy for <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>18</volume>, no. <issue>6</issue> (<year>2003</year>): <fpage>647</fpage>&#x02013;<lpage>654</lpage>.<pub-id pub-id-type="pmid">12969092</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="hsr270432-cit-0055">
<string-name>
<given-names>A.</given-names>
<surname>McNicholl</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Linares</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Nyssen</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Calvet</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Gisbert</surname>
</string-name>, &#x0201c;<article-title>Meta&#x02010;Analysis: Esomeprazole or Rabeprazole vs. First&#x02010;Generation Pump Inhibitors in the Treatment of <italic toggle="yes">Helicobacter pylori</italic> Infection</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>36</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>414</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">22803691</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="hsr270432-cit-0056">
<string-name>
<given-names>J. E.</given-names>
<surname>Kanu</surname>
</string-name> and <string-name>
<given-names>J.</given-names>
<surname>Soldera</surname>
</string-name>, &#x0201c;<article-title>Treatment of <italic toggle="yes">Helicobacter pylori</italic> With Potassium Competitive Acid Blockers: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>World Journal of Gastroenterology</source>
<volume>30</volume>, no. <issue>9</issue> (<year>2024</year>): <fpage>1213</fpage>&#x02013;<lpage>1223</lpage>.<pub-id pub-id-type="pmid">38577188</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="hsr270432-cit-0057">
<string-name>
<given-names>E.</given-names>
<surname>Kahramano&#x0011f;lu Aksoy</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Pirin&#x000e7;ci Sapmaz</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>G&#x000f6;kta&#x0015f;</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Uzman</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Nazl&#x00131;g&#x000fc;l</surname>
</string-name>, &#x0201c;<article-title>Comparison of <italic toggle="yes">Helicobacter pylori</italic> Eradication Rates of 2&#x02010;Week Levofloxacin&#x02010;Containing Triple Therapy, Levofloxacin&#x02010;Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First&#x02010;Line Regimen</article-title>,&#x0201d; <source>Medical Principles and Practice</source>
<volume>26</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>523</fpage>&#x02013;<lpage>529</lpage>.<pub-id pub-id-type="pmid">29131124</pub-id>
</mixed-citation></ref><ref id="hsr270432-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="hsr270432-cit-0058">
<string-name>
<given-names>F.</given-names>
<surname>Alsohaibani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Peedikayil</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Alshahrani</surname>
</string-name>, et al., &#x0201c;<article-title>Practice Guidelines for the Management of <italic toggle="yes">Helicobacter pylori</italic> Infection: The Saudi <italic toggle="yes">H. pylori</italic> Working Group Recommendations</article-title>,&#x0201d; <source>Saudi Journal of Gastroenterology</source>
<volume>29</volume>, no. <issue>6</issue> (<year>2023</year>): <fpage>326</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">36204804</pub-id>
</mixed-citation></ref></ref-list></back></article>